Linnaeus Therapeutics

Linnaeus Therapeutics, Inc.Linnaeus Therapeutics, Inc. specializes in the research and development of cancer therapies, with a foundation year of 2016 in the United States. The company was founded by Christopher Natale and is headquartered in Haddonfield, New Jersey.Linnaeus Therapeutics, Inc. specializes in the development of innovative cancer therapies, particularly focusing on their lead product, LNS8801. This therapy targets metastatic cutaneous melanoma and is informed by clinical insights from the Ridky lab at the University of Pennsylvania. Their customer base primarily includes healthcare providers and institutions in oncology, as well as patients with various cancer types, including melanoma, pancreatic ductal adenocarcinoma, and non-small cell lung cancer.Linnaeus Therapeutics generates revenue through partnerships and collaborations within the biotechnology and pharmaceutical sectors, particularly centered on the clinical development of their flagship product, LNS8801. Revenue is primarily realized through co-development agreements or licensing arrangements with research institutions and pharmaceutical companies, which entail milestone payments and royalties on future sales.Linnaeus Therapeutics, Inc. The company is also strategizing to expand into European markets, pending regulatory approval by 2023, to increase its product accessibility. These initiatives aim to strengthen their pipeline and commercial viability in the competitive oncology landscape.

1. Series B

   Sep 17, 2019

   Amount

   $12M

   Investors

   Locked

2. Series A

   Nov 13, 2018

   Amount

   Undisclosed

   Investors

   Locked